Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B., Fujiwara, K., Tewari, K. S., O'Malley, D. M., Davidson, S. A., Rubin, S. C., DiSilvestro, P., Basen-Engquist, K., Huang, H., Chan, J. K., Spirtos, N. M., Ashfaq, R., & Mannel, R. S. (n.d.). bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet oncology, 18(6), 779–791. http://access.bl.uk/ark:/81055/vdc_100046742673.0x00005d